Does Rallies track congressional trades in ABBV?

Yes. Rallies tracks politician and congressional stock disclosures for ABBV, including reported purchases, sales, dates, owners, and trade amounts when available.

Is ABBV research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ABBV. It does not provide personalized investment advice.

ABBV (AbbVie) Stock Analysis - Politician Trades

AbbVie (ABBV) is a publicly traded Healthcare sector company. As of May 20, 2026, ABBV trades at $212.66 with a market cap of $369.98B and a P/E ratio of 104.75. ABBV moved -0.58% today. Year to date, ABBV is -3.58%; over the trailing twelve months it is +14.85%. Its 52-week range spans $163.81 to $244.81. Analyst consensus is strong buy with an average price target of $254.11. Rallies surfaces ABBV's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Which politicians traded ABBV stock?

Recent politician trading activity in ABBV includes disclosures from Julie Johnson, Julia Letlow, Julie Johnson, Lisa McClain, and Lisa McClain. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.

ABBV Key Metrics

Key financial metrics for ABBV
Metric	Value
Price	$212.66
Market Cap	$369.98B
P/E Ratio	104.75
EPS	$2.03
Dividend Yield	1.73%
52-Week High	$244.81
52-Week Low	$163.81
Volume	3.02M
Avg Volume	0
Revenue (TTM)	$62.82B
Net Income	$3.64B
Gross Margin	70.68%

Congressional Trades in ABBV

Julie Johnson sale ABBV on Dec 18, 2025 (amount: $15.00K) for Joint.
Julia Letlow sale ABBV on Dec 8, 2025 (amount: $15.00K).
Julie Johnson sale ABBV on Nov 13, 2025 (amount: $15.00K) for Joint.
Lisa McClain sale ABBV on Oct 31, 2025 (amount: $15.00K) for Spouse.
Lisa McClain sale ABBV on Oct 30, 2025 (amount: $15.00K) for Spouse.

Latest ABBV News

DDW Reveals Risankizumab Lowers Steroid Use from 34% to 7% and Upadacitinib Reduces Hospitalizations 31% — May 5, 2026
AbbVie jumps as Q1 results drive raised 2026 profit outlook and key-drug momentum — Apr 30, 2026
Bank of America Raises AbbVie Price Target to $234, Allergan Aesthetics Pledges $100K Donation — Apr 30, 2026
AbbVie Raises 2026 Outlook to $14.28, Triggers $18M Oncology Milestone — Apr 29, 2026
AbbVie falls despite Q1 beat as Humira erosion and FDA CRL rattle sentiment — Apr 29, 2026

Recent ABBV Insider Trades

Purdue David Ryan sold 5.23K (~$1.22M) on Mar 4, 2026.
Siatis Perry C sold 5.78K (~$1.35M) on Mar 2, 2026.
Siatis Perry C sold 10.29K (~$2.41M) on Mar 2, 2026.

ABBV Analyst Consensus

20 analysts cover ABBV: 0 strong buy, 15 buy, 5 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $254.11.

Common questions about ABBV

Which politicians traded ABBV stock?: Recent politician trading activity in ABBV includes disclosures from Julie Johnson, Julia Letlow, Julie Johnson, Lisa McClain, and Lisa McClain. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
Does Rallies track congressional trades in ABBV?: Yes. Rallies tracks politician and congressional stock disclosures for ABBV, including reported purchases, sales, dates, owners, and trade amounts when available.
Is ABBV research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ABBV. It does not provide personalized investment advice.